Metastatic thymoma with myasthenia gravis. Complete remission with combination chemotherapy

Butler, William M.; Diehl, Louis F.; Taylor, H. Grant; Weltz, Martin D.

doi:10.1002/1097-0142(19820801)50:3<419::aid-cncr2820500306>3.0.co;2-a

Cited by 26 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chemotherapy is usually well tolerated by these patients: in fact, no deterioration was observed either in our experience [53,54] or by others [76,125,[135][136][137]; partial remission may be observed [135], and this should be considered an additional evidence of the efficacy of chemotherapy on the tumour and an adjunctive marker to monitor response [107] to treatment, in an attempt to improve patient's clinical status before surgery.…”

Section: Multimodality Approachmentioning

confidence: 57%

“…Anthracycline and cisplatin are the basis of most of the protocols. In a literature review [105], an overall response rate of 84% was obtained with regimens containing this drug; however, durable (lasting several months up to 10 years) and substantial (up to 58%) responses have been observed also in patients receiving non-platinum-containing regimens [80,[106][107][108][109]. To date, the best results in phase II studies have been obtained with the PAC and ADOC regimen (cisplatin, doxorubicin, vincristine and cyclophosphamide) [110], with a higher response rate for the latter association (92% vs 50%) and a comparable median duration of response [110,111].…”

Section: Chemotherapymentioning

confidence: 99%

See 1 more Smart Citation

Thymoma and thymic carcinoma

Venuta

Anile

Diso

et al. 2010

European Journal of Cardio-Thoracic Surgery

184

152

View full text Add to dashboard Cite

Thymoma and thymic carcinoma are an extremely heterogeneous group of neoplastic lesions with an exceedingly wide spectrum of morphologic appearances. They show different presentations with a variable and unpredictable evolution ranging from an indolent non-invasive attitude to a highly infiltrative and metastasising one. Prognosis can be predicted on the basis of a number of variables, mainly staging, the WHO histological pattern and diameter of the tumour. Complete surgical resection is certainly the gold standard to achieve cure. However, especially in patients with lesions at advanced stage, complete resection may be difficult and recurrence often occurs; at these stages, disease-free long-term survival may be difficult to be accomplished. Chemo- and radiotherapy protocols have been designed to complete surgical treatment and improve results in inoperable patients as well, based on the reported sensitivity of thymic tumours to these treatment modalities. The integration of clinical staging and histology, with the new histogenetic morphological classification, has contributed to design multimodality treatment protocols that help to improve prognosis. Induction therapy can now be applied before surgery in patients with tumours considered inoperable, improving resectability and outcome without adding morbidity and mortality to the surgical procedure. This newly developed approach helps to reduce the recurrence rate and to ameliorate disease-free survival. New therapies are now being evaluated as for many other tumours; however, they still need confirmation in prospective randomised studies. In the future, integrated treatment modality should be incorporated in a standardised approach that goes from a careful assessment of histology, staging and lymph node status, and a constructive and non-empirical co-operation between medical and radiation oncologists, pathologists and thoracic surgeons.

show abstract

Section: Multimodality Approachmentioning

confidence: 57%

Section: Chemotherapymentioning

confidence: 99%

Thymoma and thymic carcinoma

Venuta

Anile

Diso

et al. 2010

European Journal of Cardio-Thoracic Surgery

184

152

View full text Add to dashboard Cite

show abstract

“…Durable responses have been observed also with nonplatinum-based regimens. [72][73][74][75] Overall, to date the best results in a Phase II study have been obtained with either a PAC or ADOC (cisplatin, doxorubicin, vincristine, cyclophosphamide) regimen, 76,77 with a higher response rate for ADOC. In particular, Fornasiero et al included 37 patients at stages III and IV with an overall response rate of 92% and complete remission in 43%.…”

Section: Chemotherapymentioning

confidence: 99%

Thymoma and thymic carcinoma

Venuta

Rendina

Anile

et al. 2012

Gen Thorac Cardiovasc Surg

View full text Add to dashboard Cite

Thymic tumors comprise a heterogeneous group of neoplasms with a wide spectrum of clinical presentations. The evolution of the disease is often unpredictable, ranging from an indolent attitude to the possibility of intra- and extrathoracic spread. From the histological point of view, thymoma and thymic carcinoma are the most frequent subtypes and arise only from thymic epithelial cells. Other histological types are even more rare and are usually considered separately. A number of prognostic factors have been validated as predictors of outcome: staging, World Health Organization histological classification, diameter of the tumor, associated paraneoplastic syndromes, completeness of resection, and early onset of recurrence. Complete surgical resection is the key factor for cure and should be considered the gold standard at any stage. Especially for more aggressive lesions, surgery should be considered with a multimodality approach, involving induction and adjuvant therapy according to the stage. Multimodality therapy protocols have been designed based on the integration of clinical staging and histology. Neoadjuvant therapy is now administered before surgical resection in patients with tumors considered inoperable as it improves resectability and survival and reduces the risk of recurrence. Adjuvant treatment has been extensively reported after both complete or partial resection. New targeted therapies are in the developmental stage, and in the future they will be part of the standard protocols. Integrated treatment modalities require strict cooperation between medical and radiation oncologists, thoracic surgeons, and pathologists.

show abstract